Literature DB >> 26731576

Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo.

Zhenhua Chen1, Ting Yu2, Bangfen Zhou1, Jinhuan Wei1, Yong Fang1, Jun Lu1, Ling Guo3, Wei Chen4, Zhi-Ping Liu5, Junhang Luo6.   

Abstract

Emerging evidence indicates that combination of two or more therapeutic strategies can synergistically enhance antitumor activity in cancer therapy. Here, we established a green method of generating nanocomposite particles that can be fabricated using catechin, a natural anti-cancer compound from green tea, and Mg(2+) in an easy one-step approach at room temperature. We show that Mg(II)-Catechin nanocomposite particles (Mg(II)-Cat NPs) have good biocompatibility and high cellular uptake also can load and effectively deliver small interfering RNA (siRNA) into cells in vitro and to tumor site in vivo. Mg(II)-Cat NPs by themselves had tumor-suppression effects. When complexed with siRNA that targets oncogene eukaryotic translation initiation factor 5A2 (EIF5A2), Mg(II)-Cat/siEIF5A2 complex had further enhanced anti-tumor activity. Mechanistically, we show that Mg(II)-Cat/siEIF5A2 inhibits oncogenic PI3K/Akt signal pathway. More importantly, Mg(II)-Cat/siEIF5A2 had tumor suppression effect in a clinically-relevant rat in-situ bladder cancer model. Our studies demonstrated that combination of Mg(II)-Cat NPs and siRNA is a promising therapeutic modality of combining chemotherapy with gene therapy in order to afford higher therapeutic efficacy and provided a proof of principle for such modality in a pre-clinical setting.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; EIF5A2; Gene therapy; Mg(II)-Catechin; Nanocomposite

Mesh:

Substances:

Year:  2015        PMID: 26731576     DOI: 10.1016/j.biomaterials.2015.11.022

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  An Overview of siRNA Delivery Strategies for Urological Cancers.

Authors:  Nadia Halib; Nicola Pavan; Carlo Trombetta; Barbara Dapas; Rossella Farra; Bruna Scaggiante; Mario Grassi; Gabriele Grassi
Journal:  Pharmaceutics       Date:  2022-03-27       Impact factor: 6.525

2.  Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells.

Authors:  Cheng Chen; Bojia Zhang; Shanshan Wu; Yongxiang Song; Jian Li
Journal:  Oncol Lett       Date:  2018-01-22       Impact factor: 2.967

3.  Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.

Authors:  Ping Sun; Wei Huang; Mingji Jin; Qiming Wang; Bo Fan; Lin Kang; Zhonggao Gao
Journal:  Int J Nanomedicine       Date:  2016-09-27

Review 4.  Recent insights into eukaryotic translation initiation factors 5A1 and 5A2 and their roles in human health and disease.

Authors:  Gao-Qi Wu; Yan-Ming Xu; Andy T Y Lau
Journal:  Cancer Cell Int       Date:  2020-04-29       Impact factor: 5.722

5.  Interactions Between lncRNA TUG1 and miR-9-5p Modulate the Resistance of Breast Cancer Cells to Doxorubicin by Regulating eIF5A2.

Authors:  Shuqian Wang; Mengjing Cheng; Xiaoxiao Zheng; Li Zheng; Hao Liu; Jianju Lu; Yu Liu; Wei Chen
Journal:  Onco Targets Ther       Date:  2020-12-23       Impact factor: 4.147

6.  Magnesium in Combinatorial With Valproic Acid Suppressed the Proliferation and Migration of Human Bladder Cancer Cells.

Authors:  Tianye Li; Yang Yu; Hang Shi; Yuhua Cao; Xiangfu Liu; Zhenzhen Hao; Yuping Ren; Gaowu Qin; Yongye Huang; Bing Wang
Journal:  Front Oncol       Date:  2020-12-11       Impact factor: 6.244

Review 7.  Properties of flavonoids in the treatment of bladder cancer (Review).

Authors:  Yue Lv; Zhonghao Liu; Haixing Jia; Youcheng Xiu; Zan Liu; Leihong Deng
Journal:  Exp Ther Med       Date:  2022-09-19       Impact factor: 2.751

Review 8.  Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer.

Authors:  Yasuyoshi Miyata; Tomohiro Matsuo; Kyohei Araki; Yuichiro Nakamura; Yuji Sagara; Kojiro Ohba; Hideki Sakai
Journal:  Medicines (Basel)       Date:  2018-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.